CD274 and non-small cell lung carcinoma: The use of immune-checkpoint inhibitors (ICIs), specifically those targeting PD-1 or its programmed cell death ligand-1 (PD-L1), yields a durable response and prolongs the survival of patients with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression (1).